Download PDF
Semin Respir Crit Care Med 2010; 31(2): 243-254
DOI: 10.1055/s-0030-1249120
© Thieme Medical Publishers

Viral Infections in Lung Transplant Recipients

Pali Dedhiya Shah1 , John F. McDyer2
  • 1Division of Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
  • 2Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
Further Information

Publication History

Publication Date:
30 March 2010 (online)

    Permissions and Reprints

ABSTRACT

Viral infections, including β-herpes viruses and community respiratory viruses, are frequent pathogens in lung transplant recipients. These pathogens have become increasingly recognized as having a significant role in long-term outcomes of lung transplantation, which has been limited by the frequent development of infections, and chronic allograft dysfunction. Community respiratory viruses, such as influenza and respiratory syncytial virus have been associated with both acute rejection and chronic allograft dysfunction, particularly if early treatment was not administered. β-herpes viruses, particularly cytomegalovirus (CMV), have long been associated with increased mortality in lung transplant recipients, although the advent of effective antiviral strategies has led to improved morbidity and mortality. Because these pathogens have been associated with altered immune responses against the allograft, a better understanding of immunopathogenesis of viral infections may lead to a broader approach to limit the morbidity from these pathogens.

KEYWORDS

Lung transplantation - respiratory virus - cytomegalovirus

REFERENCES

  • 1 Trulock E P, Christie J D, Edwards L B et al.. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007.  J Heart Lung Transplant. 2007;  26 782-795
    CrossrefPubMedGoogle Scholar
  • 2 Kim Y J, Boeckh M, Englund J A. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection.  Semin Respir Crit Care Med. 2007;  28 222-242
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Garbino J, Gerbase M W, Wunderli W et al.. Lower respiratory viral illnesses: improved diagnosis by molecular methods and clinical impact.  Am J Respir Crit Care Med. 2004;  170 1197-1203
    CrossrefPubMedGoogle Scholar
  • 4 Milstone A P, Brumble L M, Barnes J et al.. A single-season prospective study of respiratory viral infections in lung transplant recipients.  Eur Respir J. 2006;  28 131-137
    CrossrefPubMedGoogle Scholar
  • 5 Fan J, Henrickson K J, Savatski L L. Rapid simultaneous diagnosis of infections with respiratory syncytial viruses A and B, influenza viruses A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative reverse transcription-polymerase chain reaction-enzyme hybridization assay (Hexaplex).  Clin Infect Dis. 1998;  26 1397-1402
    CrossrefPubMedGoogle Scholar
  • 6 Weinberg A, Zamora M R, Li S, Torres F, Hodges T N. The value of polymerase chain reaction for the diagnosis of viral respiratory tract infections in lung transplant recipients.  J Clin Virol. 2002;  25 171-175
    CrossrefPubMedGoogle Scholar
  • 7 McCurdy L H, Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin.  J Heart Lung Transplant. 2003;  22 745-753
    CrossrefPubMedGoogle Scholar
  • 8 Hopkins P, McNeil K, Kermeen F et al.. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus.  Am J Respir Crit Care Med. 2008;  178 876-881
    CrossrefPubMedGoogle Scholar
  • 9 Falsey A R, Formica M A, Walsh E E. Diagnosis of respiratory syncytial virus infection: comparison of reverse transcription-PCR to viral culture and serology in adults with respiratory illness.  J Clin Microbiol. 2002;  40 817-820
    CrossrefPubMedGoogle Scholar
  • 10 McIntosh K, McAdam A J. Human metapneumovirus—an important new respiratory virus.  N Engl J Med. 2004;  350 431-433
    CrossrefPubMedGoogle Scholar
  • 11 Vilchez R A, Dauber J, McCurry K, Iacono A, Kusne S. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function.  Am J Transplant. 2003;  3 116-120
    CrossrefPubMedGoogle Scholar
  • 12 Mahalingam S, Schwarze J, Zaid A et al.. Perspective on the host response to human metapneumovirus infection: what can we learn from respiratory syncytial virus infections?.  Microbes Infect. 2006;  8 285-293
    CrossrefPubMedGoogle Scholar
  • 13 Kurt-Jones E A, Popova L, Kwinn L et al.. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus.  Nat Immunol. 2000;  1 398-401
    CrossrefPubMedGoogle Scholar
  • 14 Sha Q, Truong-Tran A Q, Plitt J R, Beck L A, Schleimer R P. Activation of airway epithelial cells by toll-like receptor agonists.  Am J Respir Cell Mol Biol. 2004;  31 358-364
    CrossrefPubMedGoogle Scholar
  • 15 Delgado M F, Coviello S, Monsalvo A C et al.. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease.  Nat Med. 2009;  15 34-41
    CrossrefPubMedGoogle Scholar
  • 16 Graham B S, Rutigliano J A, Johnson T R. Respiratory syncytial virus immunobiology and pathogenesis.  Virology. 2002;  297 1-7
    CrossrefPubMedGoogle Scholar
  • 17 Crowe Jr J E, Williams J V. Immunology of viral respiratory tract infection in infancy.  Paediatr Respir Rev. 2003;  4 112-119
    CrossrefPubMedGoogle Scholar
  • 18 Castilow E M, Olson M R, Varga S M. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease.  Immunol Res. 2007;  39 225-239
    CrossrefPubMedGoogle Scholar
  • 19 Olson M R, Varga S M. CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease.  J Immunol. 2007;  179 5415-5424
    PubMedGoogle Scholar
  • 20 Tsitsikas D A, Oakervee H, Cavenagh J D, Gribben J, Agrawal S G, Mattes F M. Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience.  Br J Haematol. 2009;  146 574-576
    CrossrefPubMedGoogle Scholar
  • 21 Sparrelid E, Ljungman P, Ekelöf-Andström E et al.. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections.  Bone Marrow Transplant. 1997;  19 905-908
    CrossrefPubMedGoogle Scholar
  • 22 Liu V, Dhillon G S, Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients.  Transpl Infect Dis. 2009;  , Sep 15. [Epub ahead of print]
    CrossrefPubMedGoogle Scholar
  • 23 Pelaez A, Lyon G M, Force S D et al.. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection.  J Heart Lung Transplant. 2009;  28 67-71
    CrossrefPubMedGoogle Scholar
  • 24 Glanville A R, Scott A I, Morton J M et al.. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation.  J Heart Lung Transplant. 2005;  24 2114-2119
    CrossrefPubMedGoogle Scholar
  • 25 Nokes J D, Cane P A. New strategies for control of respiratory syncytial virus infection.  Curr Opin Infect Dis. 2008;  21 639-643
    CrossrefPubMedGoogle Scholar
  • 26 Zhang W, Tripp R A. RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.  J Virol. 2008;  82 12221-12231
    CrossrefPubMedGoogle Scholar
  • 27 Garantziotis S, Howell D N, McAdams H P, Davis R D, Henshaw N G, Palmer S M. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome.  Chest. 2001;  119 1277-1280
    CrossrefPubMedGoogle Scholar
  • 28 Vilchez R, McCurry K, Dauber J et al.. Influenza and parainfluenza respiratory viral infection requiring admission in adult lung transplant recipients.  Transplantation. 2002;  73 1075-1078
    CrossrefPubMedGoogle Scholar
  • 29 Hoft D F, Belshe R B. The genetic archaeology of influenza.  N Engl J Med. 2004;  351 2550-2551
    CrossrefPubMedGoogle Scholar
  • 30 Centers for Disease Control and Prevention (CDC) . Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009.  MMWR Morb Mortal Wkly Rep. 2009;  58 893-896
    PubMedGoogle Scholar
  • 31 Danziger-Isakov L A, Husain S, Mooney M L, Hannan M M. ISHLT Infectious Diseases Council . The novel 2009 H1N1 influenza virus pandemic: unique considerations for programs in cardiothoracic transplantation.  J Heart Lung Transplant. 2009;  28 1341-1347
    CrossrefPubMedGoogle Scholar
  • 32 Faix D J, Sherman S S, Waterman S H. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans.  N Engl J Med. 2009;  361 728-729
    CrossrefPubMedGoogle Scholar
  • 33 Le Goffic R, Pothlichet J, Vitour D et al.. Cutting edge: influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells.  J Immunol. 2007;  178 3368-3372
    PubMedGoogle Scholar
  • 34 Mauad T, Hajjar L A, Callegari G D et al.. Lung pathology in fatal novel human influenza A (H1N1) infection.  Am J Respir Crit Care Med. 2010;  181 72-79
    CrossrefPubMedGoogle Scholar
  • 35 McKinstry K K, Strutt T M, Buck A et al.. IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge.  J Immunol. 2009;  182 7353-7363
    CrossrefPubMedGoogle Scholar
  • 36 Sun J, Madan R, Karp C L, Braciale T J. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10.  Nat Med. 2009;  15 277-284
    CrossrefPubMedGoogle Scholar
  • 37 Vilchez R A, McCurry K, Dauber J et al.. Influenza virus infection in adult solid organ transplant recipients.  Am J Transplant. 2002;  2 287-291
    CrossrefPubMedGoogle Scholar
  • 38 Kuo J H, Hwang R. Preparation of DNA dry powder for non-viral gene delivery by spray-freeze drying: effect of protective agents (polyethyleneimine and sugars) on the stability of DNA.  J Pharm Pharmacol. 2004;  56 27-33
    CrossrefPubMedGoogle Scholar
  • 39 Vilchez R A, McCurry K, Dauber J et al.. The epidemiology of parainfluenza virus infection in lung transplant recipients.  Clin Infect Dis. 2001;  33 2004-2008
    CrossrefPubMedGoogle Scholar
  • 40 Moudgil A, Bagga A, Toyoda M, Nicolaidou E, Jordan S C, Ross D. Expression of gamma-IFN mRNA in bronchoalveolar lavage fluid correlates with early acute allograft rejection in lung transplant recipients.  Clin Transplant. 1999;  13 201-207
    CrossrefPubMedGoogle Scholar
  • 41 Winter J B, Gouw A S, Groen M, Wildevuur C, Prop J. Respiratory viral infections aggravate airway damage caused by chronic rejection in rat lung allografts.  Transplantation. 1994;  57 418-422
    CrossrefPubMedGoogle Scholar
  • 42 Walter M J, Kajiwara N, Karanja P, Castro M, Holtzman M J. Interleukin 12 p40 production by barrier epithelial cells during airway inflammation.  J Exp Med. 2001;  193 339-351
    CrossrefPubMedGoogle Scholar
  • 43 Hayney M S, Moran J, Wiegert N A, Burlingham W J. Lung transplant patients' T cell responses to influenza vaccine viruses between seasons.  Vaccine. 2008;  26 2596-2600
    CrossrefPubMedGoogle Scholar
  • 44 Mazzone P J, Mossad S B, Mawhorter S D, Mehta A C, Schilz R J, Maurer J R. The humoral immune response to influenza vaccination in lung transplant patients.  Eur Respir J. 2001;  18 971-976
    CrossrefPubMedGoogle Scholar
  • 45 Khazeni N, Bravata D M, Holty J E, Uyeki T M, Stave C D, Gould M K. Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza.  Ann Intern Med. 2009;  151 464-473
    PubMedGoogle Scholar
  • 46 Ison M G, Sharma A, Shepard J A, Wain J C, Ginns L C. Outcome of influenza infection managed with oseltamivir in lung transplant recipients.  J Heart Lung Transplant. 2008;  27 282-288
    CrossrefPubMedGoogle Scholar
  • 47 Khalifah A P, Hachem R R, Chakinala M M et al.. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death.  Am J Respir Crit Care Med. 2004;  170 181-187
    CrossrefPubMedGoogle Scholar
  • 48 Vilchez R A, Dauber J, Kusne S. Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection—myth or reality?.  Am J Transplant. 2003;  3 245-249
    CrossrefPubMedGoogle Scholar
  • 49 Cooper J D, Billingham M, Egan T International Society for Heart and Lung Transplantation et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts.  J Heart Lung Transplant. 1993;  12 713-716
    PubMedGoogle Scholar
  • 50 Kuo E, Bharat A, Goers T et al.. Respiratory viral infection in obliterative airway disease after orthotopic tracheal transplantation.  Ann Thorac Surg. 2006;  82 1043-1050
    CrossrefPubMedGoogle Scholar
  • 51 Welsh R M, Markees T G, Woda B A et al.. Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody.  J Virol. 2000;  74 2210-2218
    CrossrefPubMedGoogle Scholar
  • 52 Rossini S, Casazza A P, Engelmann E C, Havaux M, Jennings R C, Soave C. Suppression of both ELIP1 and ELIP2 in Arabidopsis does not affect tolerance to photoinhibition and photooxidative stress.  Plant Physiol. 2006;  141 1264-1273
    CrossrefPubMedGoogle Scholar
  • 53 Fishman J A, Rubin R H. Infection in organ-transplant recipients.  N Engl J Med. 1998;  338 1741-1751
    CrossrefPubMedGoogle Scholar
  • 54 Taylor D O, Edwards L B, Boucek M M et al.. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report—2007.  J Heart Lung Transplant. 2007;  26 769-781
    CrossrefPubMedGoogle Scholar
  • 55 Manuel O, Kumar D, Moussa G et al.. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis.  Transplantation. 2009;  87 719-725
    CrossrefPubMedGoogle Scholar
  • 56 Staras S A, Dollard S C, Radford K W, Flanders W D, Pass R F, Cannon M J. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994.  Clin Infect Dis. 2006;  43 1143-1151
    CrossrefPubMedGoogle Scholar
  • 57 Gillespie G M, Wills M R, Appay V et al.. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors.  J Virol. 2000;  74 8140-8150
    CrossrefPubMedGoogle Scholar
  • 58 Balthesen M, Messerle M, Reddehase M J. Lungs are a major organ site of cytomegalovirus latency and recurrence.  J Virol. 1993;  67 5360-5366
    PubMedGoogle Scholar
  • 59 Bonatti H, Tabarelli W, Ruttmann E et al.. Impact of cytomegalovirus match on survival after cardiac and lung transplantation.  Am Surg. 2004;  70 710-714
    PubMedGoogle Scholar
  • 60 Soghikian M V, Valentine V G, Berry G J, Patel H R, Robbins R C, Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients.  J Heart Lung Transplant. 1996;  15 881-887
    PubMedGoogle Scholar
  • 61 Duncan S R, Paradis I L, Yousem S A et al.. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients.  Am Rev Respir Dis. 1992;  146 1419-1425
    PubMedGoogle Scholar
  • 62 Keenan R J, Lega M E, Dummer J S et al.. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation.  Transplantation. 1991;  51 433-438
    CrossrefPubMedGoogle Scholar
  • 63 Gandhi M K, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments.  Lancet Infect Dis. 2004;  4 725-738
    CrossrefPubMedGoogle Scholar
  • 64 Söderberg-Nauclér C, Fish K N, Nelson J A. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors.  Cell. 1997;  91 119-126
    CrossrefPubMedGoogle Scholar
  • 65 Gold M C, Munks M W, Wagner M, Koszinowski U H, Hill A B, Fling S P. The murine cytomegalovirus immunomodulatory gene m152 prevents recognition of infected cells by M45-specific CTL but does not alter the immunodominance of the M45-specific CD8 T cell response in vivo.  J Immunol. 2002;  169 359-365
    PubMedGoogle Scholar
  • 66 Gerna G, Lilleri D, Rognoni V et al.. Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients.  Am J Transplant. 2009;  9 1142-1150
    CrossrefPubMedGoogle Scholar
  • 67 Weigt S S, Elashoff R M, Keane M P et al.. Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation.  Am J Transplant. 2008;  8 1512-1522
    CrossrefPubMedGoogle Scholar
  • 68 Shlobin O A, West E E, Lechtzin N et al.. Persistent cytomegalovirus-specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients.  J Immunol. 2006;  176 2625-2634
    PubMedGoogle Scholar
  • 69 Gamadia L E, Remmerswaal E B, Weel J F, Bemelman F, van Lier R A, Ten Berge I J. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease.  Blood. 2003;  101 2686-2692
    CrossrefPubMedGoogle Scholar
  • 70 Westall G P, Brooks A G, Kotsimbos T. CD8+ T-cell maturation following lung transplantation: the differential impact of CMV and acute rejection.  Transpl Immunol. 2007;  18 186-192
    CrossrefPubMedGoogle Scholar
  • 71 Pipeling M R, West E E, Osborne C M et al.. Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection.  J Immunol. 2008;  181 546-556
    PubMedGoogle Scholar
  • 72 Kerschner H, Jaksch P, Karigl G, Popow-Kraupp T, Klepetko W, Puchhammer-Stöckl E. Cytomegalovirus DNA load patterns developing after lung transplantation are significantly correlated with long-term patient survival.  Transplantation. 2009;  87 1720-1726
    CrossrefPubMedGoogle Scholar
  • 73 Egan J J, Barber L, Lomax J et al.. Detection of human cytomegalovirus antigenaemia: a rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients.  Thorax. 1995;  50 9-13
    CrossrefPubMedGoogle Scholar
  • 74 Guiver M, Fox A J, Mutton K, Mogulkoc N, Egan J. Evaluation of CMV viral load using TaqMan CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplant recipients.  Transplantation. 2001;  71 1609-1615
    CrossrefPubMedGoogle Scholar
  • 75 Bhorade S M, Sandesara C, Garrity E R et al.. Quantification of cytomegalovirus (CMV) viral load by the hybrid capture assay allows for early detection of CMV disease in lung transplant recipients.  J Heart Lung Transplant. 2001;  20 928-934
    CrossrefPubMedGoogle Scholar
  • 76 Weinberg A, Hodges T N, Li S, Cai G, Zamora M R. Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation.  J Clin Microbiol. 2000;  38 768-772
    PubMedGoogle Scholar
  • 77 Pang X L, Fox J D, Fenton J M, Miller G G, Caliendo A M, Preiksaitis J K. American Society of Transplantation Infectious Diseases Community of Practice . Interlaboratory comparison of cytomegalovirus viral load assays.  Am J Transplant. 2009;  9 258-268
    CrossrefPubMedGoogle Scholar
  • 78 Humar A. Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis.  Transplantation. 2006;  82(2, Suppl) S9-S14
    PubMedGoogle Scholar
  • 79 Solans E P, Garrity Jr E R, McCabe M, Martinez R, Husain A N. Early diagnosis of cytomegalovirus pneumonitis in lung transplant patients.  Arch Pathol Lab Med. 1995;  119 33-35
    PubMedGoogle Scholar
  • 80 Erice A, Hertz M I, Snyder L S, Englund J, Edelman C K, Balfour Jr H H. Evaluation of centrifugation cultures of bronchoalveolar lavage fluid for the diagnosis of cytomegalovirus pneumonitis.  Diagn Microbiol Infect Dis. 1988;  10 205-212
    CrossrefPubMedGoogle Scholar
  • 81 Chemaly R F, Yen-Lieberman B, Chapman J et al.. Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients.  Am J Transplant. 2005;  5 544-548
    CrossrefPubMedGoogle Scholar
  • 82 Westall G P, Michaelides A, Williams T J, Snell G I, Kotsimbos T C. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients.  J Infect Dis. 2004;  190 1076-1083
    CrossrefPubMedGoogle Scholar
  • 83 Russo M J, Sternberg D I, Hong K N et al.. Postlung transplant survival is equivalent regardless of cytomegalovirus match status.  Ann Thorac Surg. 2007;  84 1129-1134, discussion 1134–1135
    CrossrefPubMedGoogle Scholar
  • 84 Duncan S R, Grgurich W F, Iacono A T et al.. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation.  Am J Respir Crit Care Med. 1994;  150 146-152
    PubMedGoogle Scholar
  • 85 Zamora M R. Cytomegalovirus and lung transplantation.  Am J Transplant. 2004;  4 1219-1226
    CrossrefPubMedGoogle Scholar
  • 86 Ruttmann E, Geltner C, Bucher B et al.. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.  Transplantation. 2006;  81 1415-1420
    CrossrefPubMedGoogle Scholar
  • 87 Chmiel C, Speich R, Hofer M et al.. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation.  Clin Infect Dis. 2008;  46 831-839
    CrossrefPubMedGoogle Scholar
  • 88 Zamora M R, Nicolls M R, Hodges T N et al.. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation.  Am J Transplant. 2004;  4 1635-1642
    CrossrefPubMedGoogle Scholar
  • 89 Speich R, Thurnheer R, Gaspert A, Weder W, Boehler A. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation.  Transplantation. 1999;  67 315-320
    CrossrefPubMedGoogle Scholar
  • 90 Jaksch P, Zweytick B, Kerschner H et al.. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy.  J Heart Lung Transplant. 2009;  28 670-675
    CrossrefPubMedGoogle Scholar
  • 91 Limaye A P, Corey L, Koelle D M, Davis C L, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.  Lancet. 2000;  356 645-649
    CrossrefPubMedGoogle Scholar
  • 92 Valantine H A, Luikart H, Doyle R et al.. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone.  Transplantation. 2001;  72 1647-1652
    CrossrefPubMedGoogle Scholar
  • 93 Weill D, Lock B J, Wewers D L et al.. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction.  Am J Transplant. 2003;  3 492-496
    CrossrefPubMedGoogle Scholar
  • 94 Thomas L D, Milstone A P, Miller G G, Loyd J E, Stephen Dummer J. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen.  Clin Transplant. 2009;  23 476-483
    CrossrefPubMedGoogle Scholar
  • 95 Monforte V, Román A, Gavaldà J et al.. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients.  Transplant Proc. 2005;  37 4039-4042
    CrossrefPubMedGoogle Scholar
  • 96 Limaye A P, Raghu G, Koelle D M, Ferrenberg J, Huang M L, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy.  J Infect Dis. 2002;  185 20-27
    CrossrefPubMedGoogle Scholar
  • 97 Tamm M, Aboyoun C L, Chhajed P N, Rainer S, Malouf M A, Glanville A R. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome.  Am J Respir Crit Care Med. 2004;  170 1120-1123
    CrossrefPubMedGoogle Scholar
  • 98 Reddy A J, Zaas A K, Hanson K E, Palmer S M. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.  J Heart Lung Transplant. 2007;  26 1286-1292
    CrossrefPubMedGoogle Scholar
  • 99 Brestrich G, Zwinger S, Fischer A et al.. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy.  Am J Transplant. 2009;  9 1679-1684
    CrossrefPubMedGoogle Scholar
  • 100 Einsele H, Roosnek E, Rufer N et al.. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy.  Blood. 2002;  99 3916-3922
    CrossrefPubMedGoogle Scholar
  • 101 Brestrich G, Zwinger S, Roemhild A et al.. Generation of HCMV-specific T-cell lines from seropositive solid-organ-transplant recipients for adoptive T-cell therapy.  J Immunother. 2009;  32 932-940
    CrossrefPubMedGoogle Scholar
  • 102 Aris R M, Maia D M, Neuringer I P et al.. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.  Am J Respir Crit Care Med. 1996;  154(6 Pt 1) 1712-1717
    CrossrefPubMedGoogle Scholar
  • 103 Tsai D E, Douglas L, Andreadis C et al.. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial.  Am J Transplant. 2008;  8 1016-1024
    CrossrefPubMedGoogle Scholar
  • 104 Stevens S J, Verschuuren E A, Pronk I et al.. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients.  Blood. 2001;  97 1165-1171
    CrossrefPubMedGoogle Scholar
  • 105 Knoop C, Kentos A, Remmelink M et al.. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.  Clin Transplant. 2006;  20 179-187
    CrossrefPubMedGoogle Scholar
  • 106 Funch D P, Walker A M, Schneider G, Ziyadeh N J, Pescovitz M D. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients.  Am J Transplant. 2005;  5 2894-2900
    CrossrefPubMedGoogle Scholar
  • 107 Deborska-Materkowska D, Lewandowski Z, Sadowska A et al.. Fever, human herpesvirus-6 (HHV-6) seroconversion, and acute rejection episodes as a function of the initial seroprevalence for HHV-6 in renal transplant recipients.  Transplant Proc. 2006;  38 139-143
    CrossrefPubMedGoogle Scholar
  • 108 Kidd I M, Clark D A, Sabin C A et al.. Prospective study of human betaherpesviruses after renal transplantation: association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection.  Transplantation. 2000;  69 2400-2404
    CrossrefPubMedGoogle Scholar
  • 109 Neurohr C, Huppmann P, Leuchte H Munich Lung Transplant Group et al. Human herpesvirus 6 in bronchoalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome?.  Am J Transplant. 2005;  5 2982-2991
    CrossrefPubMedGoogle Scholar
  • 110 Ross D J, Chan R C, Kubak B, Laks H, Nichols W S. Bronchiolitis obliterans with organizing pneumonia: possible association with human herpesvirus-7 infection after lung transplantation.  Transplant Proc. 2001;  33 2603-2606
    CrossrefPubMedGoogle Scholar
  • 111 Christie J D, Edwards L B, Aurora P et al.. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report—2008.  J Heart Lung Transplant. 2008;  27 957-969
    CrossrefPubMedGoogle Scholar

John F McDyerM.D. 

Johns Hopkins University, 5501 Hopkins Bayview Circle

Rm. 4B51, Baltimore, MD 21224

Email: jmcdyer@jhmi.edu